Combination analysis of Bub1 and Mad2 expression in endometrial cancer: Act as a prognostic factor in endometrial cancer

Archives of Gynecology and Obstetrics

Volumn 288, Issue 1, 2013, Pages 155-165

  Li, Lin ^a   Xu, De Bin ^a   Zhao, Xiao Li ^a   Hao, Tian Yu ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

Bub1; Endometrial cancer; Mad2; Prognosis

Indexed keywords

BUB1 RELATED PROTEIN; PROTEIN MAD2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MAD2 PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN-SERINE-THREONINE KINASES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879419574     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-012-2706-7     Document Type: Article

References (46)

1. Spurdle AB, Thompson DJ, Ahmed S et al (2011) Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet 43:451-454
2. Prat J (2004) Prognostic parameters of endometrial carcinoma. Hum Pathol 35:649-662 (Pubitemid 38881074)
3. Hayata T, Kawashima Y (1987) Clinicopathologic study of eight cases of uterine body cancers associated with endometriosis interna (uterine adenomyosis). Am J Obstet Gynecol 156:663-666 (Pubitemid 17053042)
4. Falkenberry SS, Steinhoff MM, Gordinier M et al (1996) Synchronous endometrioid tumors of the ovary and endometrium: a clinicopathologic study of 22 cases. J Reprod Med 41:713-718 (Pubitemid 26367554)
5. Foth D, Nawroth F, Schmidt T et al (2001) Bilateral ovarian fibromas and endometrial adenocarcinoma in a postmenopausal patient with growing were uterine myomas. Maturitas 39:259-264 (Pubitemid 32900556)
6. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10-17 (Pubitemid 13194678)
7. Smith HO, Leslie KK, Singh M et al (2007) GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 196:386.e1-386.e11 (Pubitemid 46497934)
8. Niwa Y, Hirose K, Matsuo K et al (2005) Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett 219:183-190 (Pubitemid 40269482)
9. Park YA, Lee JW, Choi JJ et al (2012) The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma. Gynecol Oncol 124:125-133
10. Catasus L, Gallardo A, Prat J (2009) Molecular genetics of endometrial carcinoma. Diagnostic Histopathology 15:554-563
11. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
12. Solomon DA, Kim T, Diaz-Martinez LA et al (2011) Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333:1039-1043
13. Peters J (2006) The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol 7:644-656 (Pubitemid 44268210)
14. Marangos P, Carroll J (2008) Securin regulates entry into M-phase by modulating the stability of cyclin B. Nat Cell Biol 10:445-451
15. Homer H, Gui LM, Carroll J (2009) Protein functions in prophase I arrest and prometaphase progression. Science 326:991-994
16. Boyarchuk Y, Salic A, Dasso M et al (2007) Bub1 is essential for assembly of the functional inner centromere. J Cell Biol 176:919-928 (Pubitemid 46506966)
17. Kawashima SA, Yamagishi Y, Honda T (2010) Phosphorylation of H2A by Bub1 prevents chromosomal instability through localizing shugoshin. Science 327:172-177
18. Li R, Murray AW (1991) Feedback control of mitosis in budding yeast. Cell 66:519-531 (Pubitemid 121001388)
19. Li Y, Benezra R (1996) Identification of a human mitotic checkpoint gene: hsMAD2. Science 274:246-248 (Pubitemid 26353201)
20. Mapelli M, Massimiliano L, Santaguida S et al (2007) The Mad2 conformational dimmer structure and implications for the spindle assembly checkpoint. Cell 131:730-743 (Pubitemid 350087197)
21. Yamazawa K, Shimada H, Hirai M et al (2007) Serum p53 antibody as a diagnostic marker of high-risk endometrial cancer. Am J Obst Gynecol 197:505e1-505e7 (Pubitemid 350007388)
22. Koyuncuoglu M, Okyay E, Saatli B et al (2012) Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer? Gynecol Oncol 125:208-213
23. Kim HS, Park KH, Kim SA et al (2005) Frequent mutations of human Mad2, but not Bub1, in gastric cancers cause defective mitotic spindle checkpoint. Mutat Res-Fund Mol M578:187-201 (Pubitemid 41395324)
24. Myrie KA, Percy MJ, Azim JN et al (2000) Mutation and expression analysis of human Bub1 and Bub1B in aneuploid breast cancer cell lines. Cancer Lett 151:193-199 (Pubitemid 30201502)
25. Baker DJ, Jin F, Jeganathan KB et al (2009) Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity. Cancer Cell 16:475-486
26. Hoyt MA, Totis L, Roberts BT (1991) S.cerevisiae genes reqrired for cycle arrest in response to loss of microtubule function. Cell 66:507-517 (Pubitemid 121001387)
27. Cahill P, Lengauer C, Yu J et al (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392:300-303 (Pubitemid 28155105)
28. Klebig C, Korinth D, Meraldi P (2009) Bub1 regulates chromosome segregation in a kinetochore-independent manner. J Cell Biol 185:841-858
29. Scintu M, Vitale R, Prencipe M et al (2007) Genomic instability and increased expression of Bub1 and Mad2L1 genes in ductal breast carcinoma. Cancer Lett 254:298-307 (Pubitemid 47126694)
30. Mueller W, Grabsch H (2005) 7 Role of immumohistochemical expression of Bub1 protein in gastric cancer. Handbook of immunohistochemistry and in situ hybridization of human cancinomas 4: 143-149
31. Chen HJ, Feng QL, Wang XL et al (2010) Expression of mitosis checkpoint geneBub1 and BubR1 mRNA in colorectal cancer. Chin Clin Oncol 15:330-332
32. Morgan DL (2007) The cell cycle: principles of control. Published by New Science Press in association with Oxford University Press, London. ISBN 0-87893-508-8
33. Wassmann K, Benezra R (1998) Mad2 transiently associates with an APC/p55Cdc complex during mitosis. Proc Natl Acad Sci USA 95:11193-11198 (Pubitemid 28450104)
34. Kato T, Daigo Y, Aragaki M et al (2011) Overexpression of Mad2 predicts clinical outcome in primary lung cancer patients. Lung Cancer 74:124-131
35. Li GQ, Zhang HF (2004) Mad2 and p27 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol 10:3218-3220
36. Sotillo R, Hernando E, Diaz-Rodriguez E et al (2007) Mad2 everexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11:9-23 (Pubitemid 46054519)
37. Prencipe M, McGoldrick A, Perry AS et al (2010) Mad2 downregulation in hypoxia is independent of promoter hypermethylation. Cell Cycle 9:2856-2865
38. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310
39. Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093 (Pubitemid 19169804)
40. Ryan KM, Phillips AC, Vousden KH (2001) Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13:332-337 (Pubitemid 32429498)
41. Kohler MF, Berchuck A, Davidoff AM et al (1992) Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52:1622-1627
42. Sakuragi N, Watari H, Ebina Y et al (2005) Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer. Int J Cancer 116:514-519 (Pubitemid 41099186)
43. Lee EJ, Kim TJ, Kim DS et al (2010) p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathogic study of 131 cases and literature review. Gynecol Oncol 116:528-533
44. Donehower LA, Lozano G (2009) 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9:831-841
45. Tommasi S, Besaratinia A, Wilczynski SP et al (2011) Loss of Rassf1a enhances p53-mediated tumor predisposition and accelerates progression to aneuploidy. Oncogene 30:690-700
46. Lentini L, Barra V, Schillaci T et al (2012) Mad2 depletion triggers premature cellular senescence in human primary fibroblasts by activating a p53 pathway preventing aneuploid cells propagation. J Cell Physiol 227:3324-3332